+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Abu Dhabi cohort of the A1chieve study



Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Abu Dhabi cohort of the A1chieve study



Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S477-S481



The A1chieve, a multicentric (28 countries), 24-week, non-interventional study evaluated the safety and effectiveness of insulin detemir, biphasic insulin aspart and insulin aspart in people with T2DM (n = 66,726) in routine clinical care across four continents. Data was collected at baseline, at 12 weeks and at 24 weeks. This short communication presents the results for patients enrolled from Abu Dhabi. A total of 383 patients were enrolled in the study. Four different insulin analogue regimens were used in the study. Study patients had started on or were switched to biphasic insulin aspart (n = 134), insulin detemir (n = 152), insulin aspart (n = 13), basal insulin plus insulin aspart (n = 42) and other insulin combinations (n = 41). At baseline glycaemic control was poor for both insulin naïve (mean HbA1c: 9.4%) and insulin user (mean HbA1c: 9.1%) groups. After 24 weeks of treatment, both groups showed improvement in HbA1c (insulin naïve: -2.1%, insulin users: -1.8%). SADRs did not occur in any of the study patients. Major hypoglycaemic events remained same as that of baseline (0.1 events/patient-year) for insulin naïve group whereas major hypoglycaemia reduced from 0.1 events/patient-year to 0.0 events/patient-year in insulin users. Starting or switching to insulin analogues was associated with improvement in glycaemic control with a low rate of hypoglycaemia.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052117374

Download citation: RISBibTeXText

PMID: 24404486

DOI: 10.4103/2230-8210.122085


Related references

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kolkata cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S584-S587, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Saiss cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S422-S425, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Trivandrum cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S565-S568, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Hyderabad cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S547-S551, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Maharashtra cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S511-S515, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kerala cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S561-S564, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Casablanca cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S408-S412, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Rajasthan cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S526-S529, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Gujarat cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S521-S525, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Bahraini cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S461-S464, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Oman cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S482-S485, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Delhi cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S530-S533, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Kuwait cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S465-S468, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Bangalore cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S557-S560, 2014

Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Yemen cohort of the A1chieve study. Indian Journal of Endocrinology and Metabolism 17(Suppl 2): S458-S460, 2014